Write For Us

China 2019 - China's Biotech Revolution

Sponsored Post Vitamin D2 Canada Persia
Last year, 30% of all investments into US biotech start-ups came from Chinese venture funds; the Hong Kong Stock Exchange issued its first pre-commercial biotech IPOs; and US regulators for the first time approved a new cancer drug developed by a Chinese company. How will the rise of China as a biotech powerhouse affect the global biotech industry?

This session was developed in partnership with Scientific American.

- Cong Yali, Professor; Dean, Department of Medical Ethics and Health Law, Peking University, People's Republic of China.
- Xu Xun, President, Research, BGI, People's Republic of China.
- Jackson Zhu Weiyan, Chief Executive Officer and Founder, My Bio-Med, People's Republic of China.

Moderated by:
- Mariette DiChristina, Editor-in-Chief, Scientific American, USA.

Sign in or sign up to post comments.
Be the first to comment